The Danish nicotine chewing gum manufacturer Fertin Pharma A/S, whose majority shareholder is the private equity fund EQT, has acquired two companies located in Denmark and Canada.
The company located in Denmark, Medcan Pharma A/S, develops cannabis for medicinal use. The global market for pharmaceutical and medicinal use of cannabis is a growing market. The intention is that Fertin Pharma A/S's knowledge of oral administration of active pharmaceutical ingredients, e.g. in the form of chewing gum, combined with Medcan Pharma A/S's knowledge of the use of cannabinoids will prepare the companies for taking part in such growth.
Fertin Pharma A/S has also acquired the Canadian company Tab Labs Inc. that manufactures chewing gum, mints and lozenges at its headquarters in Vancouver, Canada. The acquisition will serve as Fertin Pharma A/S's way into the North American market where legalisation of cannabinoid-containing products is spreading, and which is estimated to reach a value of more than USD 1bn in 2023.